Search
Products
Community
Markets
News
Brokers
More
IN
Get started
Community
/
Ideas
/
granted EU Orphan Drug Designation for Rintatolimod
AIM ImmunoTech Inc.
granted EU Orphan Drug Designation for Rintatolimod
By AlenCiken
Follow
Follow
Feb 5, 2021
4
Cheer
Cheer
Feb 5, 2021
JUST GOT POSITIVE EU RECOMMENDATION
AIM
(old
HEB
) granted EU Orphan Drug Designation for Rintatolimod for treatment of pancreatic cancer, Hemispherx Biopharma Europe.
Rintatolimod is Ampligen
This is going to trap shorts and when they PR this is going to explode!
ema.europa.eu/en/documents/committee-report/comp-meeting-report-review-applications-orphan-designation-january-2021_en.pdf
biotech
biotechnology
biotechs
biotechstock
biotechstocks
biotehnology
Chart Patterns
Fundamental Analysis
stockstotrade
stockstowatch
Trend Analysis
AlenCiken
Follow
Also on:
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the
Terms of Use
.